Can watching the course of myotonic dystrophy unlock better care?
NCT ID NCT07732439
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This study follows 100 adults with myotonic dystrophy (types 1 or 2) for two years to understand how muscle stiffness, daily function, and heart health change over time. Researchers will look back at up to 18 months of past medical records and then track participants with clinic visits at the start, 12 months, and 24 months. The goal is to map the natural course of the disease and identify which symptoms most affect quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict how myotonic dystrophy progresses and identify which symptoms matter most to patients.
- What could go wrong
- This is an observational study, not a treatment trial, so it will not test any new therapy. The small number of participants (100) may limit how broadly the findings apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU LA TIMONE - Service des Maladies
Marseille, 13005, France
-
CHU de Lille - Hôpital
Lille, 59037, France
-
CHU de Toulouse - Hôpital
Toulouse, 40031, France
-
Centre de référence des maladies neuromusculaires
Nantes, 44093, France
-
Centre hospitalier Universitaire d'Angers
Angers, 75651, France
-
Hôpital Pitié Salpêtrière
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists hunt for biomarkers to unlock DM1 treatments
- 700-Patient study seeks key clues to muscle disease
- Brain scans reveal diabetes link to cognitive decline in rare disease
- New drug AOC 1001 tested for rare muscle disease
- Spanish researchers launch massive DM1 registry to unlock disease secrets
- New hope for muscle stiffness: experimental drug ATX-01 enters human trials